KLK3 and pachyonychia congenita: Screening guidelines advise that individuals aged 40–50 years with a family history of PC or other high-risk features should undergo annual PSA testing, those without such risk features should undergo an annual PSA test between the ages of 50 and 75 years, and screening is optional in those older than 75 years (depending on life expectancy) [10].